The treatment of drug-resistant forms of tuberculosis has been transformed over the last decade with treatment becoming more effective, safer, and treatment duration in many cases dropping to under a year. Even so, treatment can still come with serious side effects and for some, it can still last over a year and a half. In a finding that may help further reduce side effects, new research has found that the dosage of a key drug can be lowered without compromising how well it works. Tiyese Jeranji and Marcus Low report.
Seven years after over 100 community health workers were arrested during a vigil at the provincial health department’s headquarters, Bophelo House, the struggles of community healthcare workers in the Free State continue as they are still calling for job security. Refilwe Mochoari reports.
Cryptococcal meningitis is the second biggest killer of people living with HIV after tuberculosis (TB). Now, a global initiative, the Ending Cryptococcal Meningitis Deaths by 2030 Strategic Framework aims to get the gold standard drug to treat cryptococcal meningitis – flucytosine – registered in countries that need it. Amy Green reports.
As a third wave of COVID-19 looms in the Western Cape, a group of doctors at Groote Schuur Hospital’s Post-COVID-19 Lung Disease Clinic are treating patients who have recovered from COVID-19 but who suffer lingering symptoms such as fatigue and shortness of breath. Bienne Huisman paid them a visit.
The COVID-19 pandemic caused huge setbacks for the fight against TB. Now, provinces are developing TB catch-up plans. The Western Cape Department of Health will soon launch a TB dashboard as part of its “multi-sectorial TB emergency response plan”. Tiyese Jeranji reports.
It is little wonder that some TB vaccine researchers suffer from a rare syndrome that understandably threatens their mental health. Symptoms include frustration, impatience, irritability, seemingly inexplicable rage, and in the least resilient, despair. It’s called VJS or vaccine jealousy syndrome, writes Chris Bateman.
Roughly two in five people newly ill with TB worldwide are never diagnosed. In South Africa, this amounts to about 120 000 to 160 000 people per year. A large new study called XACT III is testing ways in which more people can be diagnosed and started on TB treatment more quickly. Tiyese Jeranji reports.
Developing COVID-19 vaccines in less than a year came from repurposing multiple, decade-old vaccine research platforms, but too many lives were lost, and a new goal of developing vaccines in 100 days is needed to counter the next global pathogen, experts say.
Six simple interventions are at the heart of how clinics can be part of turning the tide on TB infection. By following a checklist of good practice, clinics can be safer for patients and staff. However, most clinics are failing to implement enough of these measures, putting people at risk of getting TB while waiting at the clinic, argues representatives from the community clinic monitoring group Ritshidze.
South Africa’s first National Tuberculosis Prevalence Survey found that many people without TB symptoms nevertheless have TB disease that can be detected using chest X-rays. Accordingly, new mobile X-ray screening programmes are being piloted in a number of provinces. Tiyese Jeranji reports.
With just a tap of a finger, some people with drug-resistant tuberculosis can get in touch with a counsellor to get support over the phone. Tiyese Jeranji looks at a telephone support project that has helped keep some people with TB connected with their healthcare workers during the most difficult periods of the COVID-19 pandemic.
The national budget tabled this week shows that planned spending on public health is reduced by a massive R50.3 billion over the next three years. We cannot accept a vaccine versus health system trade-off. Government must both expedite the procurement of vaccines and ensure that provinces have the staff and other capabilities to rapidly roll them out and to maintain and improve the quality of healthcare services, argue writers from SECTION27.